Pharma companies urged by experts to embrace AI
BOSTON, UNITED STATES — Pharmaceutical industry leaders stressed the urgent need for pharmaceutical companies to adapt to rapid artificial intelligence (AI) advancements.
During the Outsourcing in Clinical Trials New England conference, experts discussed how AI is reshaping clinical trial operations and the broader pharmaceutical landscape.
Overcoming technological adoption challenges
Manny Lazaro, Senior Vice President of Clinical Operations at Cerevel Therapeutics, highlighted the industry’s historical struggle with adopting new technologies.
However, he noted that AI presents a unique opportunity to break this trend due to its transformative potential. “Our industries are terrible at adopting new technology,” Lazaro remarked, emphasizing the need for change.
Current AI applications in pharma
Brian Wehrle from Clario shared insights on AI’s current applications, such as image de-identification and analyzing historical trial protocols. He cautioned that keeping up with AI advancements requires constant adaptation.
“We code something, and a month later, we have to change the code,” Wehrle explained, illustrating the dynamic nature of AI technology.
Workforce evolution driven by AI
As AI becomes integral to clinical research, Lazaro predicted a shift in workforce requirements. Employers will increasingly seek candidates with strong analytical skills capable of managing large datasets.
This shift aims to streamline operations and reduce costs, as noted by Harry Barnett of Lubris BioPharma. Barnett emphasized that AI-assisted tools like chatbots could help cut labor expenses in multi-center trials.
Preparing for an AI-driven future
The conference underscored the necessity for pharmaceutical companies to stay ahead of AI developments. As technology evolves, adapting swiftly will be crucial for maintaining industry competitiveness.
The event highlighted that embracing AI is essential for future success in clinical trials.
By focusing on these key areas, pharmaceutical companies can better position themselves to leverage AI effectively, ensuring they remain at the forefront of innovation and efficiency in clinical research.
